BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32910233)

  • 1. Integrating baseline MR imaging biomarkers into BCLC and CLIP improves overall survival prediction of patients with hepatocellular carcinoma (HCC).
    Aliyari Ghasabeh M; Shaghaghi M; Pandey A; Ameli S; Ambale Venkatesh B; Jacob A; Pandey P; Hazhirkarzar B; Luo Y; Rezvani Habibabadi R; Khoshpouri P; Ghadimi M; Kamel IR
    Eur Radiol; 2021 Mar; 31(3):1630-1641. PubMed ID: 32910233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.
    Takeuchi S; Rohren EM; Abdel-Wahab R; Xiao L; Morris JS; Macapinlac HA; Hassan MM; Kaseb AO
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):969-978. PubMed ID: 27942837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC.
    Shaghaghi M; AliyariG Hasabeh M; Ameli S; Ghadimi M; Hazhirkarzar B; Rezvani Habibabadi R; Tang H; Khoshpouri P; Wu Q; Pandey A; Pandey P; Baghdadi A; Kamel IR
    Eur J Radiol; 2020 Dec; 133():109389. PubMed ID: 33166831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt.
    Gomaa AI; Hashim MS; Waked I
    PLoS One; 2014; 9(3):e90929. PubMed ID: 24603710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
    Li L; Gou CY; Li JY; Achakzai R; Li XH
    Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
    Grieco A; Pompili M; Caminiti G; Miele L; Covino M; Alfei B; Rapaccini GL; Gasbarrini G
    Gut; 2005 Mar; 54(3):411-8. PubMed ID: 15710992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation.
    Labeur TA; Runge JH; Klompenhouwer EG; Klümpen HJ; Takkenberg RB; van Delden OM
    Abdom Radiol (NY); 2019 Aug; 44(8):2740-2750. PubMed ID: 31069479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.
    Howell J; Pinato DJ; Ramaswami R; Arizumi T; Ferrari C; Gibbin A; Burlone ME; Guaschino G; Toniutto P; Black J; Sellers L; Kudo M; Pirisi M; Sharma R
    Oncotarget; 2017 May; 8(22):36161-36170. PubMed ID: 28212535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems.
    Giannini E; Risso D; Botta F; Romagnoli P; Malfatti F; Fumagalli A; Testa E; Podestà E; Chiarbonello B; Polegato S; Testa R
    J Intern Med; 2004 Mar; 255(3):399-408. PubMed ID: 14871465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort.
    Zhang JF; Shu ZJ; Xie CY; Li Q; Jin XH; Gu W; Jiang FJ; Ling CQ
    PLoS One; 2014; 9(3):e88182. PubMed ID: 24609114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score.
    Zhao WH; Ma ZM; Zhou XR; Feng YZ; Fang BS
    World J Gastroenterol; 2002 Apr; 8(2):237-42. PubMed ID: 11925599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiographic tumor burden score is useful for stratifying the overall survival of hepatocellular carcinoma patients undergoing resection at different Barcelona Clinic Liver Cancer stages.
    Li WF; Liu YW; Wang CC; Yong CC; Lin CC; Yen YH
    Langenbecks Arch Surg; 2023 May; 408(1):169. PubMed ID: 37121930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective validation of the Barcelona Clinic Liver Cancer staging system.
    Cillo U; Vitale A; Grigoletto F; Farinati F; Brolese A; Zanus G; Neri D; Boccagni P; Srsen N; D'Amico F; Ciarleglio FA; Bridda A; D'Amico DF
    J Hepatol; 2006 Apr; 44(4):723-31. PubMed ID: 16488051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study.
    Su L; Zhou T; Zhang Z; Zhang X; Zhi X; Li C; Wang Q; Jia C; Shi W; Yue Y; Gao Y; Cheng B
    BMC Cancer; 2016 Jul; 16():424. PubMed ID: 27387757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of pretreatment PET/CT lean body mass-corrected parameters in patients with hepatocellular carcinoma.
    Sun M; Zhang G; Guo J; Hao S; Wang Z; Fan G
    Nucl Med Commun; 2018 Jun; 39(6):564-571. PubMed ID: 29634658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma.
    Farinati F; Vitale A; Spolverato G; Pawlik TM; Huo TL; Lee YH; Frigo AC; Giacomin A; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Biasini E; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Masotto A; Trevisani F; Cillo U;
    PLoS Med; 2016 Apr; 13(4):e1002006. PubMed ID: 27116206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.
    Adhoute X; Pénaranda G; Raoul JL; Pietri O; Bronowicki JP; Castellani P; Perrier H; Monnet O; Bayle O; Oules V; Pol B; Beaurain P; Muller C; Cassagneau P; Bourlière M
    Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1414-1423. PubMed ID: 31045613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.